Dendritic Cell Based PSMA Immunotherapy for Prostate Cancer Using a CD40-Targeted Adenovirus Vector

Williams, B. Jill; Adams, Lisa K.; Boling, Susan; Carroll, Jennifer L.; Li, Xin; Rogers, Donna; Korokhov, Nikolay; Kovesdi, Imre; Pereboev, Alexander; Curiel, David T.; Mathis, J. Michael

doi:10.1371/journal.pone.0046981

Cited by 28 publications

(21 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The human transformed embryonic kidney (HEK)-293 cell line and an androgen-insensitive MHC class I-deficient mouse PCa cell line, RM-1, which is syngeneic in C57BL/6 mice [11] , were obtained from the American Type Culture Collection (ATCC; Manassas, VA, USA). The cells were cultured in Dulbecco's minimum essential medium (MEM, Mediatech Inc; Manassas, VA, USA), containing 10% fetal bovine serum (FBS; Gemini Bioproducts; Woodland, CA, USA) and 1% antibiotic-antimycotic solution (Mediatech Inc; Manassas, VA, USA) [12] and were maintained at 37 ºC in 5% CO 2 in a fully humidified incubator.…”

Section: Methodsmentioning

confidence: 99%

Dendritic cells serve as a “Trojan horse” for oncolytic adenovirus delivery in the treatment of mouse prostate cancer

Liu

et al. 2016

Acta Pharmacol Sin

View full text Add to dashboard Cite

Section: Methodsmentioning

confidence: 99%

Dendritic cells serve as a “Trojan horse” for oncolytic adenovirus delivery in the treatment of mouse prostate cancer

Liu

et al. 2016

Acta Pharmacol Sin

View full text Add to dashboard Cite

“…These receptors include c-type lectins (e.g., DEC205, DC-SIGN, CD207, LOX-1, DC-ASGPR, Dectin-1, DCIR, DCIR2, CLEC6, CLEC9A, and CLEC12A) [3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22] , as well as non-lectin receptors, including CD40 [22][23][24][25][26] , mannose receptor [27] , and integrins [28] . Antigens delivered to DCs via these receptors have been shown to elicit certain levels of antigen-specific CD8 + CTL responses in vitro in humans and/or in vivo in mice or non-human primates (NHPs).…”

Section: Research Highlightmentioning

confidence: 99%

Dendritic Cell Targeting Vaccine for HPV-Associated Cancer

Yin

Duluc

Joo

et al. 2017

Can Cell Microenviron

View full text Add to dashboard Cite

Dendritic cells (DCs) are major antigen presenting cells that can efficiently prime and activate cellular immune responses. Delivering antigens to in vivo DCs has thus been considered as a promising strategy that could allow us to mount T cell-mediated therapeutic immunity against cancers in patients.Successful development of such types of cancer vaccines that can target in vivo DCs, however, requires a series of outstanding questions that need to be addressed. These include the proper selection of which DC surface receptors, specific DC subsets and DC activators that can further enhance the efficacy of vaccines by promoting effector T cell infiltration and retention in tumors and their actions against tumors. Supplementing these areas of research with additional strategies that can counteract tumor immune evasion mechanisms is also expected to enhance the efficacy of such therapeutic vaccines against cancers. After more than a decade of study, we have concluded that antigen targeting to DCs via CD40 to evoke cellular responses is more efficient than targeting antigens to the same types of DCs via eleven other DC surface receptors tested. In recent work, we have further demonstrated that a prototype vaccine (anti-CD40-HPV16.E6/7, a recombinant fusion protein of anti-human CD40 and HPV16.E6/7 protein) for HPV16-associated cancers can efficiently activate HPV16.E6/7-specific T cells, particularly CD8 + T cells, from the blood of HPV16 + head-and-neck cancer patients. Moreover, anti-CD40-HPV16.E6/7 plus poly(I:C) can mount potent therapeutic immunity against TC-1 tumor expressing HPV16.E6/7 protein in human CD40 transgenic mice. In this manuscript, we thus highlight our recent findings for the development of novel CD40 targeting immunotherapeutic vaccines for HPV16-associated malignancies. In addition, we further discuss several of key questions that still remain to be addressed for enhancing therapeutic immunity elicited by our prototype vaccine against HPV16-associated malignancies. Dendritic cells (DCs) are the major antigen presenting cells (APCs) that can efficiently cross-prime antigen-specific CD8 + T cells [1,2] . Such functional specialty in turn makes DCs the ideal cellular targets for the rational design of vaccine against cancers. In line with these notions, Bonifaz et al. demonstrated that antigen targeting to in vivo DCs via DEC-205 using conjugates of anti-DEC-205 and antigen is far more efficient than antigen alone at eliciting antigen-specific cellular immunity [3] .For more than a decade after the initial report on DC targeting vaccines [3] , groups of scientists have been trying to RESEARCH HIGHLIGHTCancer Cell & Microenvironment 2016; 3: e1482. doi: 10.14800/ccm.1482; © 2016 by Wenjie Yin, et al.Page 2 of 6 optimize DC-targeting vaccines by delivering antigens to different DC surface receptors. These receptors include c-type lectins (e.g., DEC205, DC-SIGN, CD207, LOX-1, DC-ASGPR, Dectin-1, DCIR, DCIR2, CLEC6, CLEC9A, and CLEC12A) [3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][...

show abstract

“…CTL response generation depends on antigen (Ag) presentation on MHC t o naïve DC8 + T cells. The poor Ag presentation activity demonstrated by tumor cells [ 12 ] highlights the need for professional APCs to generate the desired CTL response. Among the several types of APCs in the body, DCs are the most suitable for this purpose.…”

Section: Cancer Immunotherapymentioning

confidence: 99%

“…Nevertheless, ex vivo gene delivery carries substantial limitations. The process is laborious, costly and time-consuming [ 12 ]. Patients must undergo cytopheresis, followed by culturing and maturation of the acquired cells, steps that must be performed for each patient separately.…”

Section: Dna Vaccinesmentioning

confidence: 99%

Polymer-Based DNA Delivery Systems for Cancer Immunotherapy

David

Golani-Armon

2016

Advances in Delivery Science and Technology

View full text Add to dashboard Cite

The use of gene delivery systems for the expression of antigenic proteins is an established means for activating a patient's own immune system against the cancer they carry. Since tumor cells are poor antigen-presenting cells, crosspresentation of tumor antigens by dendritic cells (DCs) is essential for the generation of tumor-specifi c cytotoxic T-lymphocyte responses. A number of polymer-based nanomedicines have been developed to deliver genes into DCs, primarily by incorporating tumor-specifi c, antigen-encoding plasmid DNA with polycationic molecules to facilitate DNA loading and intracellular traffi cking. Direct in vivo targeting of plasmid DNA to DC surface receptors can induce high transfection effi ciency and long-term gene expression, essential for antigen loading onto major histocompatibility complex molecules and stimulation of T-cell responses. This chapter summarizes the physicochemical properties and biological information on polymer-based non-viral vectors used for targeting DCs, and discusses the main challenges for successful in vivo gene transfer into DCs.

show abstract

Dendritic Cell Based PSMA Immunotherapy for Prostate Cancer Using a CD40-Targeted Adenovirus Vector

Cited by 28 publications

References 26 publications

Dendritic cells serve as a “Trojan horse” for oncolytic adenovirus delivery in the treatment of mouse prostate cancer

Dendritic cells serve as a “Trojan horse” for oncolytic adenovirus delivery in the treatment of mouse prostate cancer

Dendritic Cell Targeting Vaccine for HPV-Associated Cancer

Polymer-Based DNA Delivery Systems for Cancer Immunotherapy

Contact Info

Product

Resources

About